Beam Therapeutics’ Base-Edited CAR-T Placed On Hold

Latest Off-The-Shelf Therapy To Be Delayed

 
• By Andrew McConaghie

Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.

DNA bases
Beam is a pioneer of a more precise technique in which 'single-letter' editing of DNA and RNA is possible. • Source: Shutterstock

More from Business

More from Scrip